Amendments To The Claims

- --1. (Currently Amended) A composition <u>adapted for intra-articular administration</u> for the treatment and/or prevention of damaged articular cartilage of a diarthrodial joint in man or in animals, the composition comprising therapeutic amounts of: chondroitin sulfate; N-acetyl D-glucosamine; and hyaluronan.
- 2. (Original) The composition of claim 1, wherein the therapeutic amount of chondroitin sulfate comprises from between about 0.5 grams to about 1.5 grams of a suitable chondroitin sulfate per unit dose of the composition.
- 3. (Original) The composition of claim 2, wherein the suitable chondroitin sulfate is CS4 chondroitin sulfate.
- 4. (Original) The composition of claim 2, wherein the suitable chondroitin sulfate is CS6 chondroitin sulfate.
- 5. (Original) The composition of claim 2, wherein the suitable chondroitin sulfate is a mixture of CS4 chondroitin sulfate and CS6 chondroitin sulfate.
- 6. (Original) The composition of claim 1, wherein the therapeutic amount of N acetyl D-glucosamine is from about 0.5 grams to about 1.5 grams of N acetyl D-glucosamine per unit dose of the composition.
- 7. (Original) The composition of claim 1, wherein the therapeutic amount of hyaluronan is from about 10 mg to about 50 mg of hyaluronan per unit dose of the composition.

- 8. (Original) The composition of claim 1 as a sterile solution.
- 9. (Original) The composition of claim 1 as a sterile suspension.
- 10. (Currently Amended) A composition <u>adapted for parenteral administration</u> for the treatment and/or prevention of damaged articular cartilage of a diarthrodial joint in man or in animals, the composition consisting essentially of therapeutic amounts of: chondroitin sulfate; N-acetyl D-glucosamine; and hyaluronan.
- 11. (Original) A composition adapted for the treatment and/or prevention of traumatic synovitis in man or in animals, the composition comprising therapeutic amounts of: chondroitin sulfate; N-acetyl D-glucosamine; and hyaluronan.
- 12. (Original) The composition in claim 11 is wherein the therapeutic amount of chondroitin sulfate comprises from between about 0.5 grams to about 1.5 grams of a suitable chondroitin sulfate per unit dose of the composition.
- 13. (Original) The composition of claim 12, wherein the suitable chondroitin sulfate is CS4 chondroitin sulfate.
- 14. (Original) The composition of claim 12, wherein the suitable chondroitin sulfate is CS6 chondroitin sulfate.
- 15. (Original) The composition of claim 12, wherein the suitable chondroitin sulfate is a mixture of CS4 chondroitin sulfate and CS6 chondroitin sulfate.
- 16. (Original) The composition of claim 1 1, wherein the therapeutic amount of N acetyl D-glucosamine is from about 0.5 grams to about 1.5 grams of N acetyl D-glucosamine

per unit dose of the composition.

- 17. (Original) The composition of claim 11, wherein the therapeutic amount of hyaluronan is from about 10 mg to about 50 mg of hyaluronan per unit dose of the composition.
- 18. (Original) The composition of claim 11 as a sterile solution.
- 19. (Original) The composition of claim 11 as a sterile suspension.
- 20. (Original) A composition adapted for the treatment and/or prevention of traumatic synovitis in man or in animals, the composition consisting essentially of therapeutic amounts of: chondroitin sulfate; N-acetyl D-glucosamine; and hyaluronan.
- 21. (Original) A method for the treatment and/or prevention of damaged articular cartilage of a diarthrodial joint in man or in animals, comprising administering a therapeutic amount of a composition comprised of chondroitin sulfate; N-acetyl D-glucosamine; and hyaluronan.
- 22. (Original) The method in claim 21, wherein the therapeutic composition is administered intra-articular.
- 23. (Original) The method in claim 21, wherein the therapeutic composition is administered intramuscularly.
- 24. (Original) The method in claim 21, wherein the therapeutic composition is administered intravenously.
- 25. (Original) A method for the treatment and/or prevention of damaged articular

cartilage of a diarthrodial joint in man or in animals, comprising administering a therapeutic amount of a composition consisting essentially of chondroitin sulfate; N-acetyl D-glucosamine; and hyaluronan.

- 26. (Original) The method in claim 25, wherein the therapeutic composition is administered intra-articular.
- 27. (Original) The method in claim 25, wherein the therapeutic composition is administered intramuscularly.
- 28. (Original) The method in claim 25, wherein the therapeutic composition is administered intravenously.
- 29. (Original) A method for the treatment and/or prevention of a damaged synovial membrane, traumatic synovitis, in man or in animals, comprising administering a therapeutic amount of a composition comprised of chondroitin sulfate; N-acetyl D-glucosamine; and hyaluronan.
- 30. (Original) The method in claim 29, wherein the therapeutic composition is administered intra-articular.
- 31. (Original) The method in claim 29, wherein the therapeutic composition is administered intramuscularly.
- 32. (Original) The method in claim 29, wherein the therapeutic composition is administered intravenously.
- 33. (Original) A method for the treatment and/or prevention of damaged synovial

membrane, traumatic synovitis, in man or in animals, comprising administering a therapeutic amount of a composition consisting essentially of chondroitin sulfate; N-acetyl D-glucosamine; and hyaluronan.

- 34. (Original) The method in claim 33, wherein the therapeutic composition is administered intra-articular.
- 35. (Original) The method in claim 33, wherein the therapeutic composition is administered intramuscularly.
- 36. (Original) The method in claim 33, wherein the therapeutic composition is administered intravenously.--